The role of dorsal root ganglia activation and brain-derived neurotrophic factor in multiple sclerosis

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 8, 2012, Pages 1856-1865

  Zhu, Wenjun ^a   Frost, Emma E ^a   Begum, Farhana ^a   Vora, Parvez ^a   Au, Kelvin ^a   Gong, Yuewen ^a   Macneil, Brian ^a   Pillai, Prakash ^a   Namaka, Mike ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Anterograde transport; BDNF; DRG; EAE; MS; Multiple sclerosis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL; ARTICLE; DISABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LEWIS RAT; LUMBAR VERTEBRA; METABOLISM; MULTIPLE SCLEROSIS; PATHOLOGY; RAT; SPINAL GANGLION;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISABILITY EVALUATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GANGLIA, SPINAL; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LUMBAR VERTEBRAE; MULTIPLE SCLEROSIS; RATS; RATS, INBRED LEW;

ANIMALIA; RATTUS;

EID: 84864387128     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01481.x     Document Type: Article

References (47)

1. Namaka MP, Ethans K, Jensen B, et al. Multiple sclerosis. Therapeutic choices/e-therapeutic. Ottawa: Canadian Pharmacists Association Publishers, Inc; 2011; p. 309-19.
2. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol. 2008; 28: 29-45.
3. Codarri L, Fontana A, Becher B. Cytokine networks in multiple sclerosis: lost in translation. Curr Opin Neurol. 2010; 23: 205-11.
4. Zhu W, Le Dorze JA, Prout M, et al. An overview of relapsing remitting multiple sclerosis (RRMS) and current treatment options. Pharmacy Pract. 2010; 9: CE1-7.
5. Namaka M, Leong C, Prout M, et al. Emerging therapies for the management of multiple sclerosis. Clin Med Insights: Therap. 2010; 2: 1-13.
6. De Santi L, Annunziata P, Sessa E, et al. Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neurol Sci. 2009; 287: 17-26.
7. Linker R, Gold R, Luhder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol. 2009; 29: 43-68.
8. Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol. 2008; 195: 186-93.
9. Azoulay D, Vachapova V, Shihman B, et al. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol. 2005; 167: 215-8.
10. Leibrock J, Lottspeich F, Hohn A, et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature. 1989; 341: 149-52.
11. Djalali S, Holtje M, Grosse G, et al. Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J Neurochem. 2005; 92: 616-27.
12. Lykissas MG, Batistatou AK, Charalabopoulos KA, et al. The role of neurotrophins in axonal growth, guidance, and regeneration. Curr Neurovasc Res. 2007; 4: 143-51.
13. Cunha C, Brambilla R, Thomas KL. A simple role for BDNF in learning and memory?Front Mol Neurosci. 2010; 3: 1-14.
14. Nishimura K, Nakamura K, Anitha A, et al. Genetic analyses of the brain-derived neurotrophic factor (BDNF) gene in autism. Biochem Biophys Res Commun. 2007; 356: 200-6.
15. Stadelmann C, Kerschenstainer M, Misgeld T, et al. BDNF and gp145trkB in multiple sclerosis brain lesions. Brain. 2002; 125: 75-85.
16. Brandes DW. The role of glatiramer acetate in the early treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2010; 6: 329-36.
17. Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol. 2011; 235: 9-17.
18. Arnon R, Aharoni R. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J Neural Transm. 2009; 116: 1443-49.
19. Ziemssen T, Kumpfel T, Klinkert WE, et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain. 2002; 125: 2381-91.
20. Melanson M, Miao P, Eisenstat D, et al. Experimental autoimmune encephalomyelitis-induced upregulation of tumour necrosis factor-alpha in the dorsal root ganglia. Mult Scler. 2009; 15: 1135-45.
21. Begum F, Zhu W, Namaka MP, et al. A novel decalcification method for adult rodent bone for histological analysis of peripheral-central nervous system connections. J. Neurosci. Methods. 2010; 187: 59-66.
22. Miao P, Madec K, Gong Y, et al. Axotomy-induced up-regulation of tumour necrosis factor-alpha in the dorsal root ganglia. Neurol Res. 2008; 30: 623-31.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-54.
24. Chadwick W, Magnus T, Martin B, et al. Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci. 2008; 31: 504-11.
25. Grimm JW, Lu L, Hayashi T, et al. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci. 2003; 23: 742-47.
26. Mix E, Meyer-Rienecker H, Zettl U. Animal models of multiple sclerosis for the development and validation of novel therapies-potential and limitations. J. Neurol. 2008; 255: 7-14.
27. von Bartheld CS, Wang X, Butowt R. Anterograde axonal transport, transcytosis, and recycling of neurotrophic factors: the concept of trophic currencies in neural networks. Mol Neurobiol. 2001; 24: 1-28.
28. Gauthier LR, Charrin BC, Borrell-Pages M, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004; 118: 127-38.
29. Caviston JP, Holzbaur EL. Microtubule motors at the intersection of trafficking and transport. Trends Cell Biol. 2006; 16: 530-7.
30. Miki H, Okada Y, Hirokawa N. Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol. 2005; 15: 467-76.
31. Park JJ, Cawley NX, Loh YP. A bi-directional carboxypeptidase E-driven transport mechanism controls BDNF vesicle homeostasis in hippocampal neurons. Mol Cell Neurosci. 2008; 39: 63-73.
32. Mannie M, Swanborg RH, Stepaniak JA. Experimental autoimmune encephalomyelitis in the rat. Curr Protoc Immunol. 2009; 15: 15.2.
33. Skihar V, Silva C, Chojnacki A, et al. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci USA. 2009; 106: 17992-7.
34. Lalive PH, Neuhaus O, Benkhoucha M, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011; 25: 401-14.
35. La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev. 2010; 5: CD004678.
36. Makar TK, Bever CT, Singh IS, et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol. 2009; 210: 40-51.
37. Makar TK, Trisler D, Eglitis MA, et al. Brain-derived neurotrophic factor (BDNF) gene delivery into the CNS using bone marrow cells as vehicles in mice. Neurosci Lett. 2004; 356: 215-9.
38. Woolf CJ, Allchorne A, Safieh-Garabedian B, et al. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol. 1997; 121: 417-24.
39. Zhang YH, Chi XX, Nicol GD. Brain-derived neurotrophic factor enhances the excitability of rat sensory neurons through activation of the p75 neurotrophin receptor and the sphingomyelin pathway. J Physiol. 2008; 586: 3113-27.
40. Coull JAM, Beggs S, Boudreau D, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005; 438: 1017-21.
41. Aloe L, Properzi F, Probert L, et al. Learning abilities, NGF and BDNF brain levels in two lines of TNF-alpha transgenic mice, one characterized by neurological disorders, the other phenotypically normal. Brain Res. 1999; 840: 125-37.
42. Saha R, Liu X, Pahan K. Up-regulation of BDNF in astrocytes by TNF-α: A case for the neuroprotective role of cytokine. J Neuroimmun. Pharmacol. 2006; 1: 212-22.
43. Takei Y, Laskey R. Tumour necrosis factor alpha regulates responses to nerve growth factor, promoting neural cell survival but suppressing differentiation of neuroblastoma cells. Mol Biol Cell. 2008; 19: 855-64.
44. Zweifel LS, Kuruvilla R, Ginty DD. Functions and mechanisms of retrograde neurotrophin signalling. Nat Rev Neurosci. 2005; 6: 615-25.
45. Altar CA, DiStefano PS. Neurotrophin trafficking by anterograde transport. Trends Neurosci. 1998; 21: 433-7.
46. McTigue DM, Horner PJ, Stokes BT, et al. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci. 1998; 18: 5354-65.
47. Merighi A, Salio C, Ghirri A. BDNF as a pain modulator. Prog Neurobiol. 2008; 85: 297-317.